
Pegvisomant therapy in acromegalic patient resistant to other treatment: case report
Author(s) -
Emilia Nowicka,
Michał Obel,
Piotr Dzikowski,
Martyna Stefaniak,
Zofia Pietrzak,
Ewa Obel
Publication year - 2022
Publication title -
journal of education, health and sport
Language(s) - English
Resource type - Journals
ISSN - 2391-8306
DOI - 10.12775/jehs.2022.12.08.010
Subject(s) - acromegaly , pegvisomant , medicine , cabergoline , lanreotide , pituitary adenoma , transsphenoidal surgery , adenoma , octreotide , adverse effect , somatostatin , radiation therapy , endocrinology , surgery , hormone , growth hormone , prolactin